Dr Reddy’s Q1 profit misses expectations due to U.S. pricing pressure, despite 11.4% revenue growth led by India and Europe.

• North America revenue fell 11.3% on price erosion in key drugs like Lenalidomide, facing competition and patent expiry risk.
• Domestic sales rose 11%, while European revenue doubled on strong nicotine therapy demand from the Haleon acquisition.
• Net profit at ₹14.18B missed the ₹14.94B estimate; U.S. delays and competition continue to pressure the growth outlook.